The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Johnson & Johnson is a drug manufacturers - general business with stocks listed in the US. Johnson And Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
How to buy shares in Johnson And Johnson
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Johnson And Johnson. Find the share by name or ticker symbol: JNJ. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Johnson And Johnson reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Johnson And Johnson, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Johnson And Johnson. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Johnson And Johnson shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Johnson And Johnson's shares ever split?
Johnson And Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Johnson And Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson And Johnson shares which in turn could have impacted Johnson And Johnson's share price.
Johnson And Johnson shares at a glance
Information last updated 2025-12-01.
| 52-week range | US$136.504 - US$207.81 |
|---|---|
| 50-day moving average | US$191.2932 |
| 200-day moving average | US$169.3418 |
| Target price | US$202.5433 |
| PE ratio | 19.8396 |
| Dividend yield | US$5.08 (2.46%) |
| Earnings per share (TTM) | US$10.35 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Is it a good time to buy Johnson And Johnson stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Johnson And Johnson stock?
Valuing Johnson And Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson And Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson And Johnson's P/E ratio
Johnson And Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Johnson And Johnson shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson And Johnson's PEG ratio
Johnson And Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1181. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson And Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson And Johnson's EBITDA
Johnson And Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$31.9 billion (£24 billion).
The EBITDA is a measure of a Johnson And Johnson's overall financial performance and is widely used to measure stock profitability.
Johnson And Johnson share price volatility
Over the last 12 months, Johnson And Johnson's shares have ranged in value from as little as US$136.504 up to US$207.81. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson And Johnson's is 0.358. This would suggest that Johnson And Johnson's shares are less volatile than average (for this exchange).
Johnson And Johnson financials
| Revenue TTM | US$92.1 billion |
|---|---|
| Operating margin TTM | 30.2% |
| Gross profit TTM | US$63 billion |
| Return on assets TTM | 8.26% |
| Return on equity TTM | 33.62% |
| Profit margin | 27.26% |
| Book value | 32.947 |
| Market capitalisation | US$494.7 billion |
| EBITDA | US$31.9 billion |
TTM: trailing 12 months
Johnson And Johnson share dividends
Dividend payout ratio: 42.3% of net profits
Recently Johnson And Johnson has paid out, on average, around 42.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson And Johnson shareholders could enjoy a 2.53% return on their shares, in the form of dividend payments. In Johnson And Johnson's case, that would currently equate to about $5.08 per share.
While Johnson And Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson And Johnson may be investing much of the rest of its net profits in future growth.
Johnson And Johnson's most recent dividend payout was on 8 December 2025. The latest dividend was paid out to all shareholders who bought their shares by 24 November 2025 (the "ex-dividend date").
Johnson And Johnson's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson And Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Johnson And Johnson's total ESG risk score
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson And Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson And Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Johnson And Johnson's environmental score
Environmental score: 3.79/100
Johnson And Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Johnson And Johnson's social score
Social score: 25.14/100
Johnson And Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Johnson And Johnson's governance score
Governance score: 14.87/100
Johnson And Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson And Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Johnson And Johnson's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson And Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson And Johnson has a damaged public profile.
Environmental, social, and governance (ESG) summary
Johnson & Johnson was last rated for ESG on: 2019-01-01.
| Total ESG score | 35.8 |
|---|---|
| Total ESG percentile | 72.38 |
| Environmental score | 3.79 |
| Environmental score percentile | 7 |
| Social score | 25.14 |
| Social score percentile | 7 |
| Governance score | 14.87 |
| Governance score percentile | 7 |
| Level of controversy | 4 |
Johnson And Johnson overview
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Best short term investments in Australia for 2025
If you have funds to invest for 2 or years or less, you can safely earn up to 5% p.a. through a high interest savings account, bonds or ETFs.
-
How to buy Washington H. Soul Pattinson and Company shares in Australia
Steps to owning and managing Washington H. Soul Pattinson and Company shares from in Australia.
-
How to invest in copper in Australia
Copper is an industrial metal with many applications. Here’s what you should consider before investing.
-
How to invest in financial stocks in Australia
Financial stocks drive the economy and affect many aspects of a consumer’s economic life.
-
How to buy Viva Energy shares in Australia
Steps to owning and managing Viva Energy shares from in Australia.
-
How to buy Verizon shares in Australia
Steps to owning and managing Verizon shares from in Australia.
-
How to buy Wells Fargo shares in Australia
Steps to owning and managing Wells Fargo shares from in Australia.
-
How to buy Visa shares in Australia
Steps to owning and managing Visa shares from in Australia.
-
How to invest in cannabis stocks
Just 5 years ago, few investors took cannabis stocks seriously; today, as billions of dollars pour into the sector, few doubt that it will be one of the next big disruptors.
-
How to buy Uber shares in Australia
Steps to owning and managing Uber shares from in Australia.